制药巨头GSK和关系治疗伙伴开发治疗纤维化疾病和骨髓炎的治疗方法。 Pharma giants GSK and Relation Therapeutics partner to develop treatments for fibrotic diseases and osteoarthritis.

GSK和Relational Servictrications合作开发新的纤维化疾病和骨髓炎治疗方法,GSK提供4 500万美元的预付付款,今后可能支付6 300万美元。 GSK and Relation Therapeutics have partnered to develop new treatments for fibrotic diseases and osteoarthritis, with GSK providing an upfront payment of $45 million and potential future payments up to $63 million. 关系将利用其创新技术,将机器学习与人类基因数据结合起来,确定新的治疗目标。 Relation will use its innovative technology, combining machine learning with human genetics data, to identify new therapeutic targets. GSK将处理任何由此产生的药物的开发和商业化,而关系在里程碑付款和特许使用费方面可赚取高达2亿美元的收入。 GSK will handle the development and commercialization of any resulting drugs, while Relation could earn up to $200 million in milestone payments and royalties.